Protein-bound polysaccharide-K reduces colitic tumors and improves survival of inflammatory bowel disease in vivo

Oncology Letters

Volumn 2, Issue 5, 2011, Pages 791-796

  Tsutsumi, Norifumi ^a   Kohnoe, Shunji ^a,b   Sonoda, Hideto ^a,b   Guntani, Atsushi ^a   Rikimaru, Tatsuya ^a   Taguchi, Ken Ichi ^c   Tomikawa, Morimasa ^a   Kakeji, Yoshihiro ^a   Nakashima, Hideaki ^a   Maehara, Yoshihiko ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b FUKUOKA DENTAL COLLEGE   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

Colitis related cancer; Colorectal cancer; Inflammation; Protein bound polysaccharide K

Indexed keywords

ANTIINFLAMMATORY AGENT; KRESTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MORTALITY; CANCER SURVIVAL; COLON CARCINOGENESIS; COLORECTAL TUMOR; CONTROLLED STUDY; ENTERITIS; IN VIVO STUDY; MALE; MELENA; MOUSE; NONHUMAN;

EID: 79960292720     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.336     Document Type: Article

References (30)

1. Parkin DM: Global cancer statistics in the year 2000. Lancet Oncol 2: 533-543, 2001.
2. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW and Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274, 2006.
3. Tsutsumi N, Yonemitsu Y, Shikada Y, Onimaru M, Tanii M, Okano S, Kaneko K, Hasegawa M, Hashizume M, Maehara Y and Sueishi K: Essential role of PDGFRalpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo: role of PDGFRalpha during angiogenesis. Circ Res 94: 1186-1194, 2004.
4. Flossmann E and Rothwell PM: British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613, 2007.
5. Chan AT, Ogino S and Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 356: 2131-2142, 2007.
6. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I and Forbes A: Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459, 2004.
7. Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K and Orita K: Krestin (PSK). Cancer Treat Rev 11: 131-155, 1984.
8. Fisher M and Yang LX: Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. Anticancer Res 22: 1737-1754, 2002.
9. Ohwada S, Ikeya T, Yokomori T, Kusaba T, Roppongi T, Takahashi T, Nakamura S, Kakinuma S, Iwazaki S, Ishikawa H, Kawate S, Nakajima T and Morishita Y: Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. Br J Cancer 90: 1003-1010, 2004.
10. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y and Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702, 1990.
11. Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249, 1993.
12. Kohno H, Suzuki R, Sugie S and Tanaka T: Beta-catenin mutations in a mouse model of inflammation-related colon carcinogenesis induced by 1.2-dimethylhydrazine and dextran sodium sulfate. Cancer Sci 96: 69-76, 2005.
13. Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J and Ohkusa T: Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 17: 1078-1083, 2002.
14. Takesue F, Korenaga D, Yao T, Kabashima A and Sugimachi K: Development of colonic neoplasms and expressions of p53 and p21 proteins in experimental colitis of mice induced by dextran sulfate sodium. J Exp Clin Cancer Res 20: 413-418, 2001.
15. Harada M, Matsunaga K, Oguchi Y, Iijima H, Tamada K, Abe K, Takenoyama M, Ito O, Kimura G and Nomoto K: Oral administration of PSK can improve the impaired anti-tumor CD4+ T-cell response in gut-associated lymphoid tissue (GALT) of specific-pathogen-free mice. Int J Cancer 70: 362-372, 1997.
16. Brabletz T, Jung A and Kirchner T: Beta-catenin and the morphogenesis of colorectal cancer. Virchows Arch 441: 1-11, 2002.
17. Guan RJ, Fu Y, Holt PR and Pardee AB: Association of K-ras mutations with p16 methylation in human colon cancer. Gastroenterology 116: 1063-1071, 1999.
18. Hirose K, Zachariae CO, Oppenheim JJ and Matsushima K: Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 9: 475-483, 1990.
19. Kato M, Hirose K, Hakozaki M, Ohno M, Saito Y, Izutani R, Noguchi J, Hori Y, Okumoto S, Kuroda D, et al: Induction of gene expression for immunomodulating cytokines in peripheral blood mononuclear cells in response to orally administered PSK, an immunomodulating protein-bound polysaccharide. Cancer Immunol Immunother 40: 152-156, 1995.
20. Yefenof E, Gafanovitch I, Oron E, Bar M and Klein E: Prophylactic intervention in radiation-leukemia-virus-induced murine lymphoma by the biological response modifier polysaccharide K. Cancer Immunol Immunother 41: 389-396, 1995.
21. Habelhah H, Okada F, Nakai K, Choi SK, Hamada J, Kobayashi M and Hosokawa M: Polysaccharide K induces Mn superoxide dismutase (Mn-SOD) in tumor tissues and inhibits malignant progression of QR-32 tumor cells: possible roles of interferon alpha, tumor necrosis factor alpha and transforming growth factor beta in Mn-SOD induction by polysaccharide K. Cancer Immunol Immunother 46: 338-344, 1998.
22. Ohmura Y, Matsunaga K and Suzuki T: Protective effect of a protein-bound polysaccharide, PSK, on CLP-induced sepsis in mice transplanted orthotopically with colon tumor. Shock 25: 36-42, 2006.
23. Elwood PC, Gallagher AM, Duthie GG, Mur LAJ and Morgan G: Aspirin, salicylates, and cancer. Lancet 373: 1301-1309, 2009.
24. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD and Levin B: PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885-895, 2006.
25. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB and Hawk ET: APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-884, 2006.
26. Velayos FS, Terdiman JP and Walsh JM: Effect of 5-amino-salicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: 1345-1353, 2005.
27. Yoshimura A: Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 97: 439-447, 2006.
28. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF and Karin M: IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296, 2004.
29. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431: 461-466, 2004.
30. Hanada T, Kobayashi T, Chinen T, Saeki K, Takaki H, Koga K, Minoda Y, Sanada T, Yoshioka T, Mimata H, Kato S and Yoshimura A: IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice. J Exp Med 203: 1391-1397, 2006.